Upscale AI | $5,500,000 | (May 13, 2025)
Zendo | $2,310,525 | (May 13, 2025)
theom | $20,000,000 | (May 13, 2025)
Certified by Founder
Lodge
OrsoBio
start up
United States
- Palo Alto, CA
- 08/11/2023
- Series A
- $60,000,000
OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.
- Industry Biotechnology Research
- Website https://orsobio.com/
- LinkedIn https://www.linkedin.com/company/orsobio/about/
GLASS Imaging | $20,000,000 | (May 13, 2025)
Tobin Scientific | $65,000,000 | (May 13, 2025)
Axe | $1,666,102 | (May 13, 2025)
Zapia AI | $7,250,000 | (May 13, 2025)
TensorStax | $5,000,000 | (May 13, 2025)
Alt DRX | $2,700,000 | (May 13, 2025)
Miden | $25,000,000 | (May 13, 2025)
InBrain Pharma | $2,000,943 | (May 13, 2025)
Zebu Intelligent Systems Pvt Ltd | $1,000,000 | (May 9, 2025)